A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety, and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Subjects Aged 40 Years and Older
Latest Information Update: 20 Oct 2023
At a glance
- Drugs LZ-901 (Primary)
- Indications Herpes zoster
- Focus Therapeutic Use
- Sponsors Beijing Luzhu Biotechnology
Most Recent Events
- 20 Oct 2023 New trial record